People: Salix Pharmaceuticals Ltd (SLXP.O)
SLXP.O on Nasdaq
--USD
--
--USD
--
Price Change (% chg)
-- (--)
-- (--)
Prev Close
$26.97
$26.97
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
970,913
970,913
52-wk High
$29.91
$29.91
52-wk Low
$6.14
$6.14
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
| Chappell, John | 72 | 2003 | Chairman of the Board |
| Logan, Carolyn | 60 | 2002 | President, Chief Executive Officer, Director |
| Derbyshire, Adam | 43 | 2000 | Chief Financial Officer, Senior Vice President - Finance and Administration |
| Forbes, William | 47 | 2005 | Vice President - Research and Development, Chief Development Officer |
| D'Alonzo, Thomas | 65 | 2000 | Director |
| Franco, Richard | 68 | 2000 | Director |
| Keane, William | 54 | 2004 | Director |
| Sirgo, Mark | 55 | 2008 | Director |
Biographies
| Name | Description |
|---|---|
| Chappell, John | John F. Chappell is Chairman of the Board of Directors of Salix Pharmaceuticals, Ltd. HE has served as a member of the Board of Directors since December 1993 and has been the Chairman of the Board since September 2003. From 1990 until his retirement in 2000, he served as founder and Chairman of Plexus Ventures, which specializes in business development and strategic transactions for clients in the biotechnology, pharmaceutical and drug delivery industries. Prior to founding Plexus Ventures, Mr. Chappell served as Chairman, Worldwide Pharmaceuticals for SmithKline Beecham plc, now GlaxoSmithKline plc, where he was responsible for the multi-billion dollar ethical pharmaceutical business with 30,000 employees worldwide. During his 28 years at SmithKline Beecham, Mr. Chappell also headed the International Consumer Products (OTC) operations and the Corporate Development Center. He has served as a director of SmithKline Beecham, the Pharmaceutical Manufacturers Association, now PhRMA, and the Industrial Biotechnology Association, now BIO. Mr. Chappell holds a B.A. degree from Harvard University and attended the Wharton School of the University of Pennsylvania. |
| Logan, Carolyn | Carolyn J. Logan has been President and Chief Executive Officer and as a member of the Board of Directors of Salix Pharmaceuticals, Ltd., since July 2002. She previously served as Senior Vice President, Sales and Marketing from June 2000 to July 2002. Prior to joining Salix, Ms. Logan served as Vice President, Sales and Marketing of the Oclassen Dermatologics Division of Watson Pharmaceuticals, Inc. from May 1997 to June 2000, and as its Vice President, Sales from February 1997 to May 1997. Prior to that date, she served as Director, Sales of Oclassen Pharmaceuticals, Inc. from January 1993 to February 1997. Prior to joining Oclassen, Ms. Logan held various sales and marketing positions with Galderma Laboratories, Ulmer Pharmacal and Westwood Pharmaceuticals. Ms. Logan received a B.S. degree in Biology and Dental Hygiene from the University of North Carolina at Chapel Hill. |
| Derbyshire, Adam | Adam C. Derbyshire has been Senior Vice President, Finance and Administration and Chief Financial Officer of Salix Pharmaceuticals, Ltd., since June 2000. From June 1999 to June 2000, Mr. Derbyshire was Vice President, Corporate Controller and Secretary of Medco Research, Inc., acquired by King Pharmaceuticals, Inc. in February 2000, Corporate Controller and Secretary of Medco from September 1995 to June 1999 and Assistant Controller of Medco from October 1993 to September 1995. Mr. Derbyshire received his B.S. degree from the University of North Carolina at Wilmington and his MBA from the University of North Carolina at Charlotte. |
| Forbes, William | William P. Forbes has been Vice President, Research and Development and Chief Development Officer of Salix Pharmaceuticals, Ltd., since January 2005. From 2002 through 2004, Dr. Forbes was Vice President, Clinical Development and Regulatory Affairs of Metabasis Therapeutics, Inc. He has also worked for Otsuka America Pharmaceutical, Inc. in a variety of roles of increasing responsibility from 1991 to 2002 and Glaxo, Inc. from 1989 through 1991. He has extensive experience in clinical development, regulatory affairs and project management. Dr. Forbes received his Doctor of Pharmacy degree from Creighton University. |
| D'Alonzo, Thomas | Thomas W. D'Alonzo joined the Board of Directors of Salix Pharmaceuticals, Ltd. in May 2000. He has served as the Chief Executive Officer and a director of MiMedx Group, Inc. since March 2007. From May 2006 to April 2007, Mr. D’Alonzo was Chief Executive Officer of DARA BioSciences. From 2000 to 2007, Mr. D’Alonzo acted as an independent consultant. Prior to that, from 1996 to 1999, Mr. D’Alonzo served as President and Chief Operating Officer of Pharmaceutical Product Development, Inc., or PPD, a global provider of discovery and development services to pharmaceutical and biotechnology companies. Before joining PPD, from 1993 to 1996, he served as President and Chief Executive Officer of GENVEC, Inc., a clinical-stage biopharmaceutical company. From 1983 to 1993, Mr. D’Alonzo held positions of increasing responsibility within Glaxo, Inc., including President. He is currently on the Board of Directors of Amarillo Biosciences, Inc., BioDelivery Sciences International, Inc. (although he is not standing for re-election at their 2008 annual meeting of stockholders), and DARA BioSciences, Inc. Mr. D’Alonzo received his B.S. in Business Administration from the University of Delaware, and his J.D. from the University of Denver College of Law. |
| Franco, Richard | Richard A. Franco, Sr. joined the Board of Directors of Salix Pharmaceuticals, Ltd. in May 2000. Since January 2009, Mr. Franco has been Chairman and Chief Executive Officer of DARA BioSciences, Inc. Mr. Franco is President and a director of the Richards Group Ltd., a healthcare consulting firm. He served in several capacities at DARA BioSciences, Inc., a private pharmaceutical company, from 2005 until March 2008, including most recently as its President, Chief Executive Officer and Chairman. Mr. Franco served as the Chairman of the Board for LipoScience, Inc. from May 1997 to October 2002, as well as Chief Executive Officer and President from November 1997 to September 2001. Prior to co-founding LipoScience, he was President, Chief Executive Officer and a director of Trimeris Inc., a biopharmaceutical company. Prior to joining Trimeris, Mr. Franco held several senior positions and served on the Executive Committee of Glaxo, Inc. from 1983 to 1994, including Vice President and General Manager of Glaxo Dermatology, Vice President and General Manager of the Cerenex Division, Vice President of Commercial Development and Vice President of Marketing. Prior to joining Glaxo, Mr. Franco worked in various positions over a 16-year period with Eli Lilly and Company. Mr. Franco served on the Board of Directors of TriPath Imaging, Inc., now a wholly owned subsidiary of Becton, Dickinson and Company, and NeoMatrix, Inc. Mr. Franco serves as a director of the Research Triangle Chapter of the National Association of Corporate Directors (NACD). He received a B.S. in Pharmacy from St. John’s University and did his graduate work in pharmaceutical marketing and management at Long Island University. Mr. Franco has completed executive training at the Wharton School of the University of Pennsylvania, Duke University Fuqua School of Business, School of Business at the University of Michigan, Tuck School at Dartmouth College, and the Kellogg School of Management at Northwestern University. |
| Keane, William | William P. Keane joined the Board of Directors of Salix Pharmaceuticals, Ltd. in January 2004. From October 2002 until September 2005, Mr. Keane was the Chief Financial Officer and Corporate Secretary for Genta Incorporated, a biopharmaceutical company focused on the identification, development and commercialization of drugs for the treatment of patients with cancer. Prior to that, Mr. Keane was the Vice President - Sourcing, Strategy and Operations Effectiveness for Bristol-Myers Squibb Company from April 2001 until October 2002. From August 2000 until April 2001, Mr. Keane was the Chief Financial Officer for Covance Biotechnology Services, a drug development services company. From September 1997 until July 2000, Mr. Keane was the Vice President, Finance - Global Pharmaceutical Manufacturing for Warner-Lambert Company, a pharmaceutical company subsequently acquired by Pfizer Inc. Mr. Keane also serves on the Board of Directors of Intellect Neurosciences, Inc. Mr. Keane received a B.A. in Microbiology and an M.B.A. from Rutgers University. |
| Sirgo, Mark | Mark A. Sirgo joined the Board of Directors of Salix Pharmaceuticals, Ltd in February 2008. Dr. Sirgo has been the President and Chief Executive Officer of BioDelivery Sciences International, Inc., or BDSI, since July of 2005 and served in various executive positions at BDSI since August 2004. Prior to August 2004, Dr. Sirgo was the co-founder and Chief Executive Officer of Arius Pharmaceuticals, which was acquired by BDSI in August 2004. Prior to his involvement with Arius Pharmaceuticals, Dr. Sirgo spent three years as Senior Vice President of Global Sales and Marketing at Pharmaceutical Product Development, Inc., a leading contract service provider to the pharmaceutical industry, and 16 years in a variety of positions of increasing responsibility in both clinical development and marketing at Glaxo, Glaxo Wellcome, and GlaxoSmithKline, including Vice President of International OTC Development and Vice President of New Product Marketing. Dr. Sirgo received his BS in Pharmacy from The Ohio State University and his Doctorate from the Philadelphia College of Pharmacy and Science. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
| Chappell, John | -- |
| Logan, Carolyn | 1,603,970 |
| Derbyshire, Adam | 689,063 |
| Forbes, William | 583,226 |
| D'Alonzo, Thomas | -- |
| Franco, Richard | -- |
| Keane, William | -- |
| Sirgo, Mark | -- |
As Of 30 Dec 2008
Options Compensation
| Name | Options | Value |
|---|---|---|
| Chappell, John | 0 | 0 |
| Logan, Carolyn | 857,328 | 8,715,740 |
| Derbyshire, Adam | 413,128 | 4,417,029 |
| Forbes, William | 106,250 | 5,000 |
| D'Alonzo, Thomas | 0 | 0 |
| Franco, Richard | 0 | 0 |
| Keane, William | 0 | 0 |
| Sirgo, Mark | 0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
| SIRGO MARK A | 1,550 | $29.26 |
| SIRGO MARK A | 200 | $27.09 |
| SIRGO MARK A | 200 | $27.89 |
| LOGAN CAROYLN J | 550 | $0.00 |
| LOGAN CAROYLN J | 550 | $0.00 |
| LOGAN CAROYLN J | 550 | $0.00 |
| LOGAN CAROYLN J | 550 | $0.00 |
| LOGAN CAROYLN J | 35,000 | $1.13 |
| DERBYSHIRE ADAM C | 5,000 | $1.13 |
| DERBYSHIRE ADAM C | 5,000 | $23.10 |
| DERBYSHIRE ADAM C | 5,000 | $1.13 |
| DERBYSHIRE ADAM C | 5,000 | $23.37 |
| DERBYSHIRE ADAM C | 5,000 | $1.13 |
| DERBYSHIRE ADAM C | 5,000 | $23.58 |
| REETH MARK D | 3,377 | $23.64 |
| DERBYSHIRE ADAM C | 5,000 | $21.05 |
| DERBYSHIRE ADAM C | 5,000 | $1.13 |
| DERBYSHIRE ADAM C | 5,000 | $1.13 |
| DERBYSHIRE ADAM C | 5,000 | $20.12 |
| DERBYSHIRE ADAM C | 5,000 | $1.13 |
| DERBYSHIRE ADAM C | 5,000 | $19.79 |
| DERBYSHIRE ADAM C | 5,000 | $21.00 |
| DERBYSHIRE ADAM C | 5,000 | $1.13 |
| DERBYSHIRE ADAM C | 5,000 | $1.13 |
| DERBYSHIRE ADAM C | 5,000 | $22.89 |
© Copyright 2010 Thomson Reuters
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
